Currently, a definitive AD diagnosis can only be achieved at autopsy, through pathology examinations of brain tissue. No non- or less-invasive examination can yet diagnose and characterize AD during the patient’s life, in turn limiting insights into potential strategies for countering AD modes of progression. Here, using HRMAS MRS, we studied human blood plasma samples obtained from AD and non-AD subjects to reveal potential AD-associated metabolomic changes measurable in blood, which may assist with AD diagnosis and, more importantly, contribute to the development of precision treatments.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords